Poor
Needs Revision
Patient Risk:
Low
Summary
Only the statement identifying Mounjaro as containing tirzepatide is supported by the supplied label. The remaining claims concern pricing, insurance, discounts, competition, patents, and market exclusivity, none of which are addressed in the supplied prescribing information.
Category Scores
Accurate Statements
Mounjaro is tirzepatide.
Section 11 states that MOUNJARO contains tirzepatide.
Unsupported Statements
Mounjaro's price can vary by dose strength.
The supplied label does not address Mounjaro pricing.
Mounjaro's price can vary by pharmacy.
The supplied label does not address pharmacy pricing.
Mounjaro's price can vary based on insurance formulary status.
The supplied label does not address insurance formulary status.
Each higher-milligram Mounjaro pen can cost more.
The supplied label describes available strengths but does not provide or compare prices.
Different pharmacies can have different negotiated prices for Mounjaro.
The supplied label does not address negotiated pharmacy prices.
Mounjaro's cost can depend on whether it has preferred or non-preferred formulary placement.
The supplied label does not address formulary placement or cost.
Prior authorization or step therapy can affect access to Mounjaro and its cost.
The supplied label does not address prior authorization, step therapy, access restrictions, or cost.
Patient cost-sharing for Mounjaro can involve either a copay or coinsurance.
The supplied label does not address patient cost-sharing.
A manufacturer savings offer or pharmacy discount program can significantly reduce the price of Mounjaro for eligible patients.
The supplied label does not address savings offers, discount programs, or eligibility.
Without insurance, patients usually pay the full pharmacy price for Mounjaro unless they qualify for a savings program or another discount pathway.
The supplied label does not address uninsured pricing or discount pathways.
The out-of-pocket cost of Mounjaro can differ by dose and pharmacy.
The supplied label does not address out-of-pocket cost.
Other diabetes or weight-loss treatments in the same general class, or other GLP-1/GIP options, may be cheaper than Mounjaro depending on insurance coverage.
The supplied label does not compare Mounjaro with other treatments or address their prices or insurance coverage.
Mounjaro is protected by patent and market exclusivity rules.
The supplied label does not address patents or market exclusivity.
Patent and market exclusivity rules affect when other manufacturers can sell competing versions of Mounjaro.
The supplied label does not address competing versions or market exclusivity.
If competition becomes available, pricing pressure on Mounjaro can follow.
The supplied label does not discuss competition or future pricing effects.
The timing and impact of competition for Mounjaro depend on specific patent estates and patent challenges.
The supplied label does not address patent estates, patent challenges, or competition timing.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims do not provide clinical dosing or safety instructions and do not directly conflict with the supplied label. However, the predominantly unsupported pricing and market-related claims could be financially misleading if presented as label-derived information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Most claims are not supported by the supplied prescribing information and address pricing, insurance, discounts, patents, and competition rather than labeled drug information.
Suggested Improvement
Limit label-based claims to information supported by the prescribing information, such as that Mounjaro contains tirzepatide. Clearly identify any pricing, insurance, discount, patent, or market statements as information outside the supplied label and verify them with appropriate non-label sources.